Products

Vronogabic

Pregabalin 75 mg
Pregabalin 150 mg

Expand All
Collapse All

Active ingredient

Pregabalin 75 mg
Pregabalin 150 mg
 

Indications

  • Management of neuropathic pain associated with diabetic peripheral neuropathy.
  • Management of postherpetic neuralgia.
  • Adjunctive therapy for adult patients with partial onset seizures.
  • Management of fibromyalgia.

Dosage and Administration

Recommended effective dose:
- 1 capsule 75 mg b.i.d.
- Increased after 3 to 7 days interval to 1 capsule 150 mg b.i.d based on individual patient response.

Contraindication

Hypersensitivity to the active substance or to any of the excipients.

Side effects

  • Dizziness.
  • Somnolence. 

Drug Interaction

  • In vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and other AEDs, lorazepam, oxycodone or ethanol.
  • Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.
  • No clinically significant drug-drug interaction with the oral contraceptives norethisterone and/or ethinyl oestradiol.

Pregnancy and Lactation

Pregnancy
There are no adequate data from the use of pregabalin in pregnant women. 
Lactation
Breast-feeding is not recommended during treatment with pregabalin.

Warning and Precaution

Renal impairment: Because renal elimination is the major elimination pathway, dosage reduction in patients with renal impairment and dosage supplementation following haemodialysis is necessary.

Package and Storage

• Package:
‚Äč- Carton box containing 2 strips each of 10 hard gelatin capsules & insert leaflet.
• Storage:
- Store at temperature not exceeding 30°C in a dry place.
- Keep out of reach of children.

Mother Company

Manufactured by Marcyrl